{
"@context": "https://schema.org",
"@graph": [
{
"@type": "WebPage",
"@id": "https://www.fortrea.com/insights/non-invasive-biomarkers-promising-future-reduce-patients-burden-and-accelerate-drug#webpage",
"url": "https://www.fortrea.com/insights/non-invasive-biomarkers-promising-future-reduce-patients-burden-and-accelerate-drug",
"name": "Non-invasive biomarkers: Promising future to reduce patients’ burden and accelerate drug development in MASH",
"description": "Explore this Fortrea white paper focused on how non-invasive biomarkers can reduce patient burden and accelerate drug development in MASH. The white paper examines biomarker-driven approaches supporting non-invasive clinical research, patient-focused development strategies, disease monitoring, clinical trial optimization, and improved efficiency across metabolic dysfunction-associated steatohepatitis development programs. It also highlights the growing role of non-invasive approaches in advancing MASH therapeutic development while addressing challenges associated with patient participation, clinical evaluation, and biomarker integration in MASH clinical research."
},
{
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "Home",
"item": "https://www.fortrea.com"
},
{
"@type": "ListItem",
"position": 2,
"name": "Insights",
"item": "https://www.fortrea.com/insights/"
},
{
"@type": "ListItem",
"position": 3,
"name": "Non-invasive biomarkers: Promising future to reduce patients’ burden and accelerate drug development in MASH",
"item": "https://www.fortrea.com/insights/non-invasive-biomarkers-promising-future-reduce-patients-burden-and-accelerate-drug"
}
]
},
{
"@type": "Organization",
"@id": "https://www.fortrea.com/#organization",
"name": "Fortrea",
"url": "https://www.fortrea.com",
"description": "Fortrea is a global contract research organization built on more than 30 years of experience and one of the earliest CRO legacies in the industry—as Covance, evolving within Labcorp, and now operating as Fortrea. With deep expertise across Phase I–IV clinical trials, Fortrea advances clinical research through a patient-centric approach that prioritizes meaningful outcomes, stronger site–CRO relationships, and operational excellence. Fortrea partners with biopharmaceutical, biotech, and medical device companies to advance therapies through every stage of clinical development. This commitment is further reinforced by the launch of Fortrea Intelligent Technology, enabling smarter, more connected, and data-driven clinical development. Through Fortrea Intelligent Technology, the organization is advancing data-driven, technology-enabled clinical development to improve speed, quality, and patient outcomes. It is shaped by experience, innovation, and a commitment to raising standards in clinical research—focused on accelerating development and helping bring life-changing treatments to patients around the world.",
"logo": "https://www.fortrea.com/sites/default/files/2025-05/fortrea-logo-without-background.png",
"sameAs": [
"https://www.linkedin.com/company/fortrea",
"https://www.threads.net/@fortreacro",
"https://twitter.com/fortrea",
"https://www.youtube.com/@Fortrea/",
"https://www.facebook.com/Fortrea-104143099267108",
"https://www.instagram.com/fortreacro"
]
},
{
"@type": "Article",
"@id": "https://www.fortrea.com/insights/non-invasive-biomarkers-promising-future-reduce-patients-burden-and-accelerate-drug#whitepaper",
"mainEntityOfPage": {
"@id": "https://www.fortrea.com/insights/non-invasive-biomarkers-promising-future-reduce-patients-burden-and-accelerate-drug#webpage"
},
"headline": "Non-Invasive Biomarkers Reducing Patient Burden and Accelerating Drug Development in MASH | Fortrea White Paper",
"description": "Explore this Fortrea white paper focused on how non-invasive biomarkers can reduce patient burden and accelerate drug development in MASH. The white paper examines biomarker-driven approaches supporting non-invasive clinical research, patient-focused development strategies, disease monitoring, clinical trial optimization, and improved efficiency across metabolic dysfunction-associated steatohepatitis development programs. It also highlights the growing role of non-invasive approaches in advancing MASH therapeutic development while addressing challenges associated with patient participation, clinical evaluation, and biomarker integration in MASH clinical research.",
"genre": "White Paper",
"image": {
"@type": "ImageObject",
"url": "https://www.fortrea.com/sites/default/files/2025-09/non-invasive-biomarkers-mash-drug-development.jpg"
},
"author": {
"@type": "Organization",
"name": "Fortrea",
"url": "https://www.fortrea.com/"
},
"publisher": {
"@id": "https://www.fortrea.com/#organization"
},
"datePublished": "2025-09-01",
"dateModified": "2025-09-01",
"encoding": {
"@type": "MediaObject",
"contentUrl": "https://www.fortrea.com/sites/default/files/2025-09/non-invasive-biomarkers-future-mash-drug-development-updated.pdf",
"encodingFormat": "application/pdf"
}
}
]
}